Abbott to Buy Cardiovascular Systems for $890M | Twin Cities Business
New Brighton-based Cardiovascular Systems is slated to bring new, complementary products to Abbott's existing offerings.
Stay updated with breaking news from Sam Eiber. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
New Brighton-based Cardiovascular Systems is slated to bring new, complementary products to Abbott's existing offerings.
BTIG analysts maintained their neutral rating for Embecta (Nasdaq:EMBC) ahead of the company's fourth-quarter earnings report next week.
Masimo is rolling out a software upgrade that will enable millions of high-end home entertainment systems to become health information hubs.
Masimo reported third-quarter results that beat the consensus forecast on Wall Street — but it held down its Q4 guidance.
Embecta (Nasdaq:EMBC), the BD diabetes business spinoff, may take a few years to move into a growth phase, analysts say.